Cabozantinib, an oral TKI targeting VEGFR2, MET, AXL, RET, KIT and FLT3 that was approved by the FDA in 2016 for patients with advanced RCC, who had formerly been treated with one or more antiangiogenic drugs [34], was not investigated in the current study. This evidence concerns the gene FLT3 and renal cell carcinoma.